Healthcare provider profile · identity verified

Lydecke B Sweet, MD

Internal Medicine · CHARLESTOWN, MA · NPI 1639160146

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	461	129
Amlodipine Besylate	Amlodipine Besylate	295	86
Omeprazole	Omeprazole	278	80
Levothyroxine Sodium	Levothyroxine Sodium	220	52
Lisinopril	Lisinopril	189	59
Eliquis	Apixaban	154	28
Lorazepam	Lorazepam	128	27
Gabapentin	Gabapentin	122	41
Metoprolol Succinate	Metoprolol Succinate	116	40
Hydrochlorothiazide	Hydrochlorothiazide	109	34
Albuterol Sulfate Hfa	Albuterol Sulfate	108	27
Mounjaro	Tirzepatide	108	15
Simvastatin	Simvastatin	108	30
Losartan Potassium	Losartan Potassium	102	33
Metformin Hcl	Metformin Hcl	100	32
Trazodone Hcl	Trazodone Hcl	89	26
Famotidine	Famotidine	85	17
Rosuvastatin Calcium	Rosuvastatin Calcium	84	29
Metformin Hcl Er	Metformin Hcl	76	19
Trulicity	Dulaglutide	76	18
Ibuprofen	Ibuprofen	73	19
Sertraline Hcl	Sertraline Hcl	71	23
Ozempic	Semaglutide	66	12
Clonazepam	Clonazepam	61	15
Duloxetine Hcl	Duloxetine Hcl	61	22
Alendronate Sodium	Alendronate Sodium	58	18
Furosemide	Furosemide	55	22
Ondansetron Hcl	Ondansetron Hcl	54	24
Escitalopram Oxalate	Escitalopram Oxalate	52	19
Fluticasone Propionate	Fluticasone Propionate	52	19
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	51	18
Propranolol Hcl Er	Propranolol Hcl	51	suppressed
Citalopram Hbr	Citalopram Hydrobromide	47	16
Tamsulosin Hcl	Tamsulosin Hcl	47	14
Jardiance	Empagliflozin	45	12
Synthroid	Levothyroxine Sodium	44	12
Tizanidine Hcl	Tizanidine Hcl	42	13
Carvedilol	Carvedilol	41	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	40	suppressed
Diclofenac Sodium	Diclofenac Sodium	37	18
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	37	13
Oxycodone Hcl	Oxycodone Hcl	36	14
Lidocaine	Lidocaine	35	12
Xarelto	Rivaroxaban	35	suppressed
Atenolol	Atenolol	34	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	33	suppressed
Tramadol Hcl	Tramadol Hcl	33	suppressed
Bupropion Xl	Bupropion Hcl	31	suppressed
Ezetimibe	Ezetimibe	31	suppressed
Breo Ellipta	Fluticasone/Vilanterol	29	suppressed
Metoprolol Tartrate	Metoprolol Tartrate	29	suppressed
Pantoprazole Sodium	Pantoprazole Sodium	28	suppressed
Pregabalin	Pregabalin	27	suppressed
Spironolactone	Spironolactone	27	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	26	suppressed
Ventolin Hfa	Albuterol Sulfate	26	11
Valsartan	Valsartan	25	suppressed
Warfarin Sodium	Warfarin Sodium	25	suppressed
Doxycycline Monohydrate	Doxycycline Monohydrate	24	19
Quetiapine Fumarate	Quetiapine Fumarate	24	suppressed
Doxepin Hcl	Doxepin Hcl	23	suppressed
Prednisone	Prednisone	23	14
Valacyclovir	Valacyclovir Hcl	23	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	22	suppressed
Lamotrigine	Lamotrigine	22	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	22	15
Wegovy	Semaglutide	22	suppressed
Allopurinol	Allopurinol	21	suppressed
Alyacen	Norethindrone-Ethin. Estradiol	21	suppressed
Finasteride	Finasteride	21	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	21	suppressed
Combivent Respimat	Ipratropium/Albuterol Sulfate	20	suppressed
Mirtazapine	Mirtazapine	20	suppressed
Lurasidone Hcl	Lurasidone Hcl	19	suppressed
Butalbital-Acetaminophen-Caffe	Butalb/Acetaminophen/Caffeine	18	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	18	suppressed
Pravastatin Sodium	Pravastatin Sodium	18	suppressed
Chlorthalidone	Chlorthalidone	17	suppressed
Glipizide	Glipizide	17	suppressed
Klor-Con M20	Potassium Chloride	17	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	17	suppressed
Clotrimazole	Clotrimazole	16	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	16	suppressed
Sucralfate	Sucralfate	16	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	16	suppressed
Cilostazol	Cilostazol	15	suppressed
Estradiol	Estradiol	15	suppressed
Fenofibrate	Fenofibrate	15	suppressed
Modafinil	Modafinil	15	suppressed
Amoxicillin	Amoxicillin	14	suppressed
Bupropion Hcl Sr	Bupropion Hcl	14	suppressed
Buspirone Hcl	Buspirone Hcl	14	suppressed
Ketoconazole	Ketoconazole	14	suppressed
Nitroglycerin	Nitroglycerin	14	suppressed
Potassium Chloride	Potassium Chloride	14	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	14	suppressed
Baclofen	Baclofen	13	suppressed
Buprenorphine Hcl	Buprenorphine Hcl	13	suppressed
Clopidogrel	Clopidogrel Bisulfate	13	suppressed
Divalproex Sodium	Divalproex Sodium	13	suppressed
Varenicline Tartrate	Varenicline Tartrate	13	suppressed
Multaq	Dronedarone Hcl	12	suppressed
Mupirocin	Mupirocin	12	suppressed
Pilocarpine Hcl	Pilocarpine Hcl	12	suppressed
Prazosin Hcl	Prazosin Hcl	12	suppressed
Tiotropium Bromide	Tiotropium Bromide	12	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	12	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	11	suppressed
Avonex Pen (4 Pack)	Interferon Beta-1a	11	suppressed
Ipratropium Bromide	Ipratropium Bromide	11	suppressed
Nifedipine Er	Nifedipine	11	suppressed
Nystatin	Nystatin	11	suppressed
Yuvafem	Estradiol	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error